Athos Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Athos Capital’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-55,000	Closed	-$7.26M	–	54
2025 Q1	$7.26M	Buy	+55,000	New	+$6.85M	8.63%	2

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Athos Capital's ITCI Position: Q2 2025 in Review

Athos Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 55,000 shares — an estimated $7.26M sold.

Athos Capital first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $7.26M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Athos Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Athos Capital sold 55,000 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $7.26M.
Athos Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Athos Capital's Intra-Cellular Therapies Inc. position peaked at $7.26M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Athos Capital's 13F filing for Q2 2025, filed 14 Aug 2025.